Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.

Grünewald S, Politz O, Bender S, Héroult M, Lustig K, Thuss U, Kneip C, Kopitz C, Zopf D, Collin MP, Boemer U, Ince S, Ellinghaus P, Mumberg D, Hess-Stumpp H, Ziegelbauer K.

Int J Cancer. 2019 Sep 1;145(5):1346-1357. doi: 10.1002/ijc.32224. Epub 2019 Mar 13.

2.

Sleep restriction alters reactive aggressive behavior and its relationship with sex hormones.

MacDonald KJ, Lustig KA, Geniole SN, McCormick CM, Cote KA.

Aggress Behav. 2019 Mar;45(2):193-205. doi: 10.1002/ab.21809. Epub 2018 Dec 30.

PMID:
30597570
3.

Novel non-xanthine antagonist of the A2B adenosine receptor: From HTS hit to lead structure.

Härter M, Kalthof B, Delbeck M, Lustig K, Gerisch M, Schulz S, Kast R, Meibom D, Lindner N.

Eur J Med Chem. 2019 Feb 1;163:763-778. doi: 10.1016/j.ejmech.2018.11.045. Epub 2018 Nov 20.

PMID:
30576906
4.

Discovery of Rogaratinib (BAY 1163877): a pan-FGFR Inhibitor.

Collin MP, Lobell M, Hübsch W, Brohm D, Schirok H, Jautelat R, Lustig K, Bömer U, Vöhringer V, Héroult M, Grünewald S, Hess-Stumpp H.

ChemMedChem. 2018 Mar 6;13(5):437-445. doi: 10.1002/cmdc.201700718. Epub 2018 Feb 16.

PMID:
29451369
5.

Sex hormones play a role in vulnerability to sleep loss on emotion processing tasks.

Lustig KA, Stoakley EM, MacDonald KJ, Geniole SN, McCormick CM, Cote KA.

Neurobiol Sleep Circadian Rhythms. 2017 Oct 12;5:94-104. doi: 10.1016/j.nbscr.2017.10.001. eCollection 2018 Jun.

6.

Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.

Follmann M, Ackerstaff J, Redlich G, Wunder F, Lang D, Kern A, Fey P, Griebenow N, Kroh W, Becker-Pelster EM, Kretschmer A, Geiss V, Li V, Straub A, Mittendorf J, Jautelat R, Schirok H, Schlemmer KH, Lustig K, Gerisch M, Knorr A, Tinel H, Mondritzki T, Trübel H, Sandner P, Stasch JP.

J Med Chem. 2017 Jun 22;60(12):5146-5161. doi: 10.1021/acs.jmedchem.7b00449. Epub 2017 Jun 12.

7.

Potent and Selective Human Neutrophil Elastase Inhibitors with Novel Equatorial Ring Topology: in vivo Efficacy of the Polar Pyrimidopyridazine BAY-8040 in a Pulmonary Arterial Hypertension Rat Model.

von Nussbaum F, Li VM, Meibom D, Anlauf S, Bechem M, Delbeck M, Gerisch M, Harrenga A, Karthaus D, Lang D, Lustig K, Mittendorf J, Schäfer M, Schäfer S, Schamberger J.

ChemMedChem. 2016 Jan 19;11(2):199-206. doi: 10.1002/cmdc.201500269. Epub 2015 Sep 3.

PMID:
26333652
8.

Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases.

von Nussbaum F, Li VM, Allerheiligen S, Anlauf S, Bärfacker L, Bechem M, Delbeck M, Fitzgerald MF, Gerisch M, Gielen-Haertwig H, Haning H, Karthaus D, Lang D, Lustig K, Meibom D, Mittendorf J, Rosentreter U, Schäfer M, Schäfer S, Schamberger J, Telan LA, Tersteegen A.

ChemMedChem. 2015 Jul;10(7):1163-73. doi: 10.1002/cmdc.201500131. Epub 2015 Jun 17.

9.

A novel highly potent therapeutic antibody neutralizes multiple human chemokines and mimics viral immune modulation.

Scalley-Kim ML, Hess BW, Kelly RL, Krostag AR, Lustig KH, Marken JS, Ovendale PJ, Posey AR, Smolak PJ, Taylor JD, Wood CL, Bienvenue DL, Probst P, Salmon RA, Allison DS, Foy TM, Raport CJ.

PLoS One. 2012;7(8):e43332. doi: 10.1371/journal.pone.0043332. Epub 2012 Aug 17.

10.

Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling.

Weber O, Willmann S, Bischoff H, Li V, Vakalopoulos A, Lustig K, Hafner FT, Heinig R, Schmeck C, Buehner K.

Br J Clin Pharmacol. 2012 Feb;73(2):219-31. doi: 10.1111/j.1365-2125.2011.04064.x.

11.

Volume to dissolve applied dose (VDAD) and apparent dissolution rate (ADR): tools to predict in vivo bioavailability from orally applied drug suspensions.

Muenster U, Pelzetter C, Backensfeld T, Ohm A, Kuhlmann T, Mueller H, Lustig K, Keldenich J, Greschat S, Göller AH, Gnoth MJ.

Eur J Pharm Biopharm. 2011 Aug;78(3):522-30. doi: 10.1016/j.ejpb.2011.01.023. Epub 2011 Feb 16.

PMID:
21315152
12.
13.

Chromanol derivatives--a novel class of CETP inhibitors.

Vakalopoulos A, Schmeck C, Thutewohl M, Li V, Bischoff H, Lustig K, Weber O, Paulsen H, Elias H.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):488-91. doi: 10.1016/j.bmcl.2010.10.110. Epub 2010 Oct 26.

PMID:
21084191
14.

Identification and optimization of substituted 5-aminopyrazoles as potent and selective adenosine A1 receptor antagonists.

Griebenow N, Bärfacker L, Meier H, Schneider D, Teusch N, Lustig K, Kast R, Kolkhof P.

Bioorg Med Chem Lett. 2010 Oct 1;20(19):5891-4. doi: 10.1016/j.bmcl.2010.07.095. Epub 2010 Aug 1.

PMID:
20728355
15.

Glycine amides as PPARalpha agonists.

Urbahns K, Woltering M, Nikolic S, Pernerstorfer J, Bischoff H, Dittrich-Wengenroth E, Lustig K.

Bioorg Med Chem Lett. 2010 Jun 1;20(11):3376-9. doi: 10.1016/j.bmcl.2010.04.019. Epub 2010 Apr 13.

PMID:
20452212
16.
17.

Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.

Schäfer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, Milting H, Kast R, Klein M.

Cardiovasc Res. 2009 Apr 1;82(1):30-9. doi: 10.1093/cvr/cvp002. Epub 2009 Jan 8.

PMID:
19131365
18.

AAV2/1-TNFR:Fc gene delivery prevents periodontal disease progression.

Cirelli JA, Park CH, MacKool K, Taba M Jr, Lustig KH, Burstein H, Giannobile WV.

Gene Ther. 2009 Mar;16(3):426-36. doi: 10.1038/gt.2008.174. Epub 2008 Dec 11.

19.

Alpha-mercaptoketone based histone deacetylase inhibitors.

Wash PL, Hoffman TZ, Wiley BM, Bonnefous C, Smith ND, Sertic MS, Lawrence CM, Symons KT, Nguyen PM, Lustig KD, Guo X, Annable T, Noble SA, Hager JH, Hassig CA, Malecha JW.

Bioorg Med Chem Lett. 2008 Dec 15;18(24):6482-5. doi: 10.1016/j.bmcl.2008.10.058. Epub 2008 Oct 17.

PMID:
18954984
20.

Biphenyls as potent vitronectin receptor antagonists. Part 3: Squaric acid amides.

Urbahns K, Härter M, Albers M, Schmidt D, Stelte-Ludwig B, Brüggemeier U, Vaupel A, Keldenich J, Lustig K, Tsujishita H, Gerdes C.

Bioorg Med Chem Lett. 2007 Nov 15;17(22):6151-4. Epub 2007 Sep 14.

PMID:
17910915
21.
22.

Thalamocortical connections in the pond turtle Pseudemys scripta elegans.

Zhu D, Lustig KH, Bifulco K, Keifer J.

Brain Behav Evol. 2005;65(4):278-92. Epub 2005 Mar 8.

PMID:
15761219
23.

Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors.

Sandalon Z, Bruckheimer EM, Lustig KH, Rogers LC, Peluso RW, Burstein H.

J Virol. 2004 Nov;78(22):12355-65.

24.

Role of LXRs in control of lipogenesis.

Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B.

Genes Dev. 2000 Nov 15;14(22):2831-8.

25.

Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers.

Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, Mangelsdorf DJ.

Science. 2000 Sep 1;289(5484):1524-9.

26.

Identification of a nuclear receptor for bile acids.

Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B.

Science. 1999 May 21;284(5418):1362-5.

27.

Cloning of Mix-related homeodomain proteins using fast retrieval of gel shift activities, (FROGS), a technique for the isolation of DNA-binding proteins.

Mead PE, Zhou Y, Lustig KD, Huber TL, Kirschner MW, Zon LI.

Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11251-6.

28.

Specific proteolysis of the kinase protein kinase C-related kinase 2 by caspase-3 during apoptosis. Identification by a novel, small pool expression cloning strategy.

Cryns VL, Byun Y, Rana A, Mellor H, Lustig KD, Ghanem L, Parker PJ, Kirschner MW, Yuan J.

J Biol Chem. 1997 Nov 21;272(47):29449-53.

29.

Expression cloning in the test tube.

King RW, Lustig KD, Stukenberg PT, McGarry TJ, Kirschner MW.

Science. 1997 Aug 15;277(5328):973-4. No abstract available.

PMID:
9281074
30.

Hyperplasia and hypertrophy of chicken cardiac myocytes during posthatching development.

Li F, McNelis MR, Lustig K, Gerdes AM.

Am J Physiol. 1997 Aug;273(2 Pt 2):R518-26.

PMID:
9277534
31.

Systematic identification of mitotic phosphoproteins.

Stukenberg PT, Lustig KD, McGarry TJ, King RW, Kuang J, Kirschner MW.

Curr Biol. 1997 May 1;7(5):338-48.

32.

Small pool expression screening: identification of genes involved in cell cycle control, apoptosis, and early development.

Lustig KD, Stukenberg PT, McGarry TJ, King RW, Cryns VL, Mead PE, Zon LI, Yuan J, Kirschner MW.

Methods Enzymol. 1997;283:83-99. No abstract available.

PMID:
9251013
33.
34.

A Xenopus nodal-related gene that acts in synergy with noggin to induce complete secondary axis and notochord formation.

Lustig KD, Kroll K, Sun E, Ramos R, Elmendorf H, Kirschner MW.

Development. 1996 Oct;122(10):3275-82.

35.

P2U purinoceptors: cDNA cloning, signal transduction mechanisms and structure-function analysis.

Lustig KD, Weisman GA, Turner JT, Garrad R, Shiau AK, Erb L.

Ciba Found Symp. 1996;198:193-204; discussion 204-7. Review.

PMID:
8879826
36.

Use of an oocyte expression assay to reconstitute inductive signaling.

Lustig KD, Kirschner MW.

Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6234-8.

37.

Functional expression and photoaffinity labeling of a cloned P2U purinergic receptor.

Erb L, Lustig KD, Sullivan DM, Turner JT, Weisman GA.

Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10449-53.

38.

Type II adenylylcyclase integrates coincident signals from Gs, Gi, and Gq.

Lustig KD, Conklin BR, Herzmark P, Taussig R, Bourne HR.

J Biol Chem. 1993 Jul 5;268(19):13900-5.

39.

Expression cloning of an ATP receptor from mouse neuroblastoma cells.

Lustig KD, Shiau AK, Brake AJ, Julius D.

Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5113-7.

40.

Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha.

Conklin BR, Farfel Z, Lustig KD, Julius D, Bourne HR.

Nature. 1993 May 20;363(6426):274-6.

PMID:
8387644
41.

Signal transduction pathways coupled to a P2U receptor in neuroblastoma x glioma (NG108-15) cells.

Lin TA, Lustig KD, Sportiello MG, Weisman GA, Sun GY.

J Neurochem. 1993 Mar;60(3):1115-25.

PMID:
8382262
42.

Extracellular ATP reversibly increases the plasma membrane permeability of transformed mouse fibroblasts to large macromolecules.

Saribaş AS, Lustig KD, Zhang X, Weisman GA.

Anal Biochem. 1993 Feb 15;209(1):45-52.

PMID:
7682037
43.
44.
45.

Rupture through the short head of the biceps muscle belly. A case report.

DiChristina DG, Lustig KA.

Clin Orthop Relat Res. 1992 Apr;(277):139-41.

PMID:
1555334
46.

Mechanisms by which extracellular ATP and UTP stimulate the release of prostacyclin from bovine pulmonary artery endothelial cells.

Lustig KD, Erb L, Landis DM, Hicks-Taylor CS, Zhang X, Sportiello MG, Weisman GA.

Biochim Biophys Acta. 1992 Feb 19;1134(1):61-72.

PMID:
1311959
47.

Detection of coincident signals by G proteins and adenylyl cyclase.

Bourne HR, Lustig KD, Wong YH, Conklin BR.

Cold Spring Harb Symp Quant Biol. 1992;57:145-8. Review. No abstract available.

PMID:
1339653
48.

Covalent incorporation of 3'-O-(4-benzoyl)benzoyl-ATP into a P2 purinoceptor in transformed mouse fibroblasts.

Erb L, Lustig KD, Ahmed AH, Gonzalez FA, Weisman GA.

J Biol Chem. 1990 May 5;265(13):7424-31.

49.

Permeabilization of transformed mouse fibroblasts by 3'-O-(4-benzoyl)benzoyl adenosine 5'-triphosphate and the desensitization of the process.

Gonzalez FA, Ahmed AH, Lustig KD, Erb L, Weisman GA.

J Cell Physiol. 1989 Apr;139(1):109-15.

PMID:
2708449
50.

The prevention of oral complications in bone-marrow transplantations by means of oral hygiene and dental intervention.

Raber-Durlacher JE, Abraham-Inpijn L, van Leeuwen EF, Lustig KH, van Winkelhoff AJ.

Neth J Med. 1989 Feb;34(1-2):98-108. Review.

PMID:
2644559

Supplemental Content

Loading ...
Support Center